


Reference: FOI.ICB-2223/177

Subject: Skin Cancer Pathway Management

*I can confirm that the ICB **does hold some of the information requested**; please see responses below:*

QUESTION	RESPONSE
<p>1. What are your current skin cancer patient clinical pathway guidelines e.g., from initial patient symptoms in a GP setting to specialist referral as well as treatment and follow-up procedures and protocol. Attached are two outdated CCG (Clinical Commissioning Group) pathway guidelines for reference.</p>  <p>Skin Cancer CCG Pathway Guidelines.docx</p>	<p>There is not an overarching BNSSG ICB (Bristol, North Somerset and South Gloucestershire) guideline across the pathway. The Remedy platform [https://remedy.bnssg.icb.nhs.uk/] provides support to GPs and initial referral, pathways thereafter are held by the Providers.</p>
<p>2. Does your skin cancer pathway include remote patient-clinic interactions (as opposed to face-to-face interactions), Yes or No and if yes, elaborate what they are and what stage in the pathway they're used e.g., teledermatology (the use of digital photography to assess patient lesions) at the GP stage.</p>	<p>Yes, this is offered to some patients. Some images are taken in primary care and some using medical illustration.</p>

<p>3. What were your latest skin cancer pathway guidelines in 2019/2020 prior to the COVID-19 pandemic (announced as a pandemic by WHO on 11 March 2020).</p>	<p>Response as per question 1.</p>
---	------------------------------------

The information provided in this response is accurate as of 3 February 2023 and has been approved for release by Lisa Manson, Director of Planning and Performance Improvement for NHS Bristol, North Somerset and South Gloucestershire ICB.